Edwards Lifesciences Price to Book Ratio 2010-2022 | EW
Historical price to book ratio values for Edwards Lifesciences (EW) over the last 10 years. The current price to book ratio for Edwards Lifesciences as of January 27, 2023 is 7.78.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Edwards Lifesciences Price/Book Ratio Historical Data |
| Date |
Stock Price |
Book Value per Share |
Price to Book Ratio |
| 2023-01-27 |
78.14 |
|
7.78 |
| 2022-09-30 |
82.63 |
$10.04 |
8.23 |
| 2022-06-30 |
95.09 |
$9.59 |
9.92 |
| 2022-03-31 |
117.72 |
$9.41 |
12.52 |
| 2021-12-31 |
129.55 |
$9.35 |
13.85 |
| 2021-09-30 |
113.21 |
$8.88 |
12.75 |
| 2021-06-30 |
103.57 |
$8.24 |
12.57 |
| 2021-03-31 |
83.64 |
$7.49 |
11.16 |
| 2020-12-31 |
91.23 |
$7.33 |
12.45 |
| 2020-09-30 |
79.82 |
$6.76 |
11.81 |
| 2020-06-30 |
69.11 |
$6.18 |
11.19 |
| 2020-03-31 |
62.87 |
$6.30 |
9.98 |
| 2019-12-31 |
77.76 |
$19.84 |
3.92 |
| 2019-09-30 |
73.30 |
$6.10 |
12.02 |
| 2019-06-30 |
61.58 |
$5.61 |
10.97 |
| 2019-03-31 |
63.78 |
$5.51 |
11.57 |
| 2018-12-31 |
51.06 |
$5.04 |
10.13 |
| 2018-09-30 |
58.03 |
$5.36 |
10.83 |
| 2018-06-30 |
48.52 |
$5.04 |
9.62 |
| 2017-12-31 |
37.57 |
$4.70 |
8.00 |
| 2017-09-30 |
36.44 |
$4.98 |
7.31 |
| 2017-06-30 |
39.41 |
$4.64 |
8.49 |
| 2017-03-31 |
31.36 |
$4.35 |
7.22 |
| 2016-12-31 |
31.23 |
$4.13 |
7.57 |
| 2018-03-31 |
46.51 |
$5.13 |
9.06 |
| 2016-09-30 |
40.19 |
$4.20 |
9.57 |
| 2016-06-30 |
33.24 |
$3.87 |
8.58 |
| 2016-03-31 |
29.40 |
$3.62 |
8.13 |
| 2015-12-31 |
26.33 |
$3.87 |
6.80 |
| 2015-09-30 |
23.70 |
$3.75 |
6.32 |
| 2015-06-30 |
23.74 |
$3.55 |
6.68 |
| 2015-03-31 |
23.74 |
$3.43 |
6.92 |
| 2014-12-31 |
21.23 |
$6.78 |
3.13 |
| 2014-09-30 |
17.03 |
$3.19 |
5.34 |
| 2014-06-30 |
14.31 |
$3.01 |
4.75 |
| 2014-03-31 |
12.36 |
$2.12 |
5.82 |
| 2013-12-31 |
10.96 |
$2.36 |
4.65 |
| 2013-09-30 |
11.61 |
$2.19 |
5.30 |
| 2013-06-30 |
11.20 |
$2.35 |
4.77 |
| 2013-03-31 |
13.69 |
$2.34 |
5.86 |
| 2012-12-31 |
15.03 |
$2.16 |
6.97 |
| 2012-09-30 |
17.90 |
$2.21 |
8.11 |
| 2012-06-30 |
17.22 |
$2.07 |
8.30 |
| 2012-03-31 |
12.12 |
$2.03 |
5.96 |
| 2011-12-31 |
11.78 |
$1.95 |
6.03 |
| 2011-09-30 |
11.88 |
$1.98 |
6.01 |
| 2011-06-30 |
14.53 |
$2.01 |
7.23 |
| 2010-12-31 |
13.47 |
$1.90 |
7.11 |
| 2010-09-30 |
11.18 |
$1.80 |
6.20 |
| 2010-06-30 |
9.34 |
$1.65 |
5.67 |
| 2010-03-31 |
8.24 |
$1.69 |
4.88 |
| 2009-12-31 |
7.24 |
$3.40 |
2.13 |
| 2011-03-31 |
14.50 |
$1.97 |
7.36 |
| 2009-09-30 |
5.83 |
$1.61 |
3.62 |
| 2009-06-30 |
5.67 |
$1.48 |
3.83 |
| 2009-03-31 |
5.05 |
$1.40 |
3.60 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical Instruments Manufacturing |
$48.354B |
$5.233B |
|
Edwards Lifesciences Corporation deals in products and technologies aimed at treating advanced cardiovascular diseases, especially structural heart disease in critically ill patients. The company is the world's leading manufacturer of tissue heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. Edwards is also a leading player in hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The company's products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), Surgical Structural Heart, and Critical Care.
|
